Insulin: Potential Negative Consequences of Early Routine Use in Patients With Type 2 Diabetes

HAROLD E. LEBOVITZ, MD, FACE

The lack of adequate insulin secretion characterizes all hyperglycemic states. When insulin action is normal, as in type 1 diabetes, there is a near total loss of insulin secretory function. In type 2 diabetes, the abnormalities in insulin secretion are multiple. One of the initial defects is a loss of the early phase of meal-stimulated insulin secretion. This is followed by an inability of the β-cell to increase insulin secretion sufficient to overcome hepatic and peripheral insulin resistance. Type 2 diabetes is characterized by a progressive decrease in both β-cell mass and secretory function so that, in most individuals, absolute insulin deficiency occurs in the late stages of the disease.

It would seem logical that the ideal treatment for type 2 diabetes should be early and continuing insulin therapy. Unfortunately, there are several characteristics of insulin treatment and insulin action in type 2 diabetes that limit the usefulness of insulin treatment and that suggest that chronic insulin therapy is best used in the later stages of diabetes when there is an absolute deficiency of insulin.

In normal physiology, β-cell insulin secretion is coupled immediately with changes in the plasma glucose level (1). The secretory response is rapid (within a minute or two), and because the half-life of insulin is ~5 min, there is little lag time in the glucose regulatory system. Endogenously secreted insulin goes via the portal vein to the liver, where ~80% of it is either metabolized or used (2). The portal vein-to-peripheral arterial insulin ratio is ~2:1. The administration of insulin exogenously eliminates the rapid regulation of plasma glucose, since the insulin must be taken up slowly and without regulation from the subcutaneous injection site. The kinetics are determined by the nature of the injected insulin formulation. Additionally, as illustrated in Fig. 1, it is necessary to create hyperinsulinemia in the periphery to achieve adequate insulin in the liver (portal-to-peripheral insulin levels ~1:2) to appropriately regulate hepatic glucose production and/or glucose uptake.

Insulin resistance as occurs in type 2 diabetes adds additional complexities to insulin administration, since it modifies the relative mitogenic insulin activity to the metabolic insulin activity. Figure 2 depicts the two intracellular pathways of insulin action: the phosphatidylinositol 3-kinase (PI 3-kinase) pathway mediates the metabolic effects of insulin, and the adapter protein Grb-2-SOS pathway mediates the mitogenic effects of insulin (3). Insulin resistance in type 2 diabetes occurs at the level of the insulin receptor substrate 1–PI 3-kinase molecular interaction and decreases only the metabolic effects of insulin (4). Replacement with insulin to overcome the deficiencies of the metabolic deficiency will result in exaggerated mitogenic activity (Fig. 3). The evidence that inhibition of PI 3-kinase activity in humans can lead to exaggerated insulin mitogenic activity comes from studies in patients with pseudoacromegaly. Pseudoacromegaly is a disorder in which acromegalic features develop in individuals who are markedly insulin resistant with significantly elevated plasma insulin levels and normal plasma growth hormone and IGF-1 levels (5–7). Investigations of insulin action on their fibroblasts in culture have shown that insulin activation of PI 3-kinase is materially reduced (32% of normal), resulting in deficient glucose transport, whereas insulin activation of mitogen-activated protein (MAP) kinase phosphorylation and thymidine incorporation into DNA is normal (8). Thus, impairment of PI 3-kinase activity increases the mitogenic activity of insulin relative to its metabolic activity, and the administration of insulin to restore metabolic activity would be expected to cause an exaggeration in mitogenic activity. The potential long-term clinical consequences of this exaggerated mitogenic activity may be related in part to the side effects associated with chronic intensive insulin therapy in patients with type 2 diabetes. This effect would not be seen in patients with type 1 diabetes, since there is no alteration in the relationship between the mitogenic and metabolic pathways.

ARE THERE UNIQUE BENEFITS TO STARTING CHRONIC INSULIN TREATMENT EARLY?—Starting chronic insulin treatment early in the course of type 2 diabetes would be advantageous if insulin treatment had a unique benefit in decreasing the rate of β-cell apoptosis and had a more durable effect in maintaining glycemic control than other antihyperglycemic agents. The available data do not support such an effect. In the UK Prospective Diabetes Study (UKPDS) insulin treatment arm, HbA1c rose progressively during the 10 years of follow-up from ~6.3 to 8.0% (9). The percentage of insulin-treated patients who maintained an HbA1c <7% was 47% at 3 years, 37% at 6 years, and 28% at 9 years and was not different from individuals treated with sulfonylureas (10). More recent studies such as the 3-year Treating...
Exogenous versus endogenous insulin action

Figure 1—Administration of exogenous insulin provides a different insulin gradient than that occurring after endogenous insulin secretion. Endogenous insulin secretion acts initially on the liver where a major portion of it is taken up and <50% reaches the peripheral tissues. Exogenously administered insulin must circulate through the peripheral tissues before it can reach the liver; therefore, peripheral hyperinsulinemia is necessary to attain adequate insulin to regulate the liver.

To Target in Type 2 Diabetes (4-T) study, which added insulin therapy to patients inadequately controlled on oral therapies, were able to achieve and maintain HbA1c at ~7% by combining multiple different insulin strategies and progressively increasing the daily doses of insulin administered (11). The consequences, as noted in the section on complications of therapy, were a progressive increase in weight and a considerable incidence of hypoglycemia.

SIDE EFFECTS ASSOCIATED WITH LONG-TERM INTENSIVE INSULIN TREATMENT OF PATIENTS WITH TYPE 2 DIABETES

Hypoglycemia and increased mortality

If chronic insulin therapy does not lead to a greater durability of glycemic control, another potential advantage would be if it caused a greater benefit in clinical outcomes than other antihyperglycemic therapies. Two long-term clinical trials have evaluated the benefit of intensive insulin therapy compared with other therapies in reducing clinical events. The University Group Diabetes Program (UGDP) was a randomized controlled trial of patients with early adult-onset diabetes treated with placebo (diet), tolbutamide, or insulin (12,13). After 8.5 years, the trial was stopped because the tolbutamide-treated group had an increase in cardiovascular mortality compared with the placebo-treated group. The insulin-treated group showed no difference in cardiovascular mortality compared with the placebo-treated group. The UKPDS randomized type 2 diabetic patients to diet, glibenclamide, chlorpropamide, or insulin treatment. At the end of 11 years of treatment, the reduction in vascular complications with insulin was no greater than that with sulfonylureas (9). Thus, there is not a long-term randomized controlled trial that shows improved outcomes in insulin-treated type 2 diabetic patients compared with other treatments.

Figure 2—Insulin has two signaling pathways within the insulin-sensitive cell: one that uses the PI-3 pathway regulates metabolic activity, and the other that uses the MAP kinase regulates mitogenic activity. In the normal cell, these activities are balanced. IRS, insulin receptor substrate. MAPKK, mitogen-activated protein kinase kinase.
moderately controlled patients increased the hazard ratio (HR) for mortality during the studies. A similar phenomenon was noted in the Normoglycemia in Intensive Care Evaluation-Survival Using Glucose Algorithm Regulation (NICE-SUGAR) study, in which intensive insulin therapy to achieve normal blood glucose levels in intensive care patients resulted in a 90-day mortality that was increased by 14% compared with individuals treated to blood glucose levels in the moderate range (~140 mg/dL) (18). The recent 4-T study of the efficacy of different insulin regimens added to oral agents in patients with type 2 diabetes demonstrated the high incidence of clinically relevant hypoglycemia in patients assigned to prandial insulin therapy (median number of events per year 5.5) and mixed insulin therapy twice a day (3.0 events per year) (11,17). Cardiovascular mortality was greater in the prandial insulin–treated group (nine events vs. four in the mixed insulin–treated group and one in the basal insulin–treated group, P = 0.002) (11).

In all of these studies, it is unclear how the episodes of severe hypoglycemia are related to the increased mortality (14–16). A recent retrospective analysis of the U.K. General Practice Research Database identified two cohorts of patients with type 2 diabetes: one with 27,965 patients whose treatment had been intensified from oral monotherapy to combination oral anfihyperglycemic therapy and the other with 20,005 patients whose monotherapy regimen had been changed to regimens that included insulin (19). The insulin-treated cohort showed a progressive increase in mortality as the treatment median HbA1c decreased from 7.5 to 6.4% (adjusted HR 1.52 [95% CI 1.32–1.76]). There was also an increase in cardiovascular events in the lower deciles of glycemic control compared with those in the 7.12–7.68 HbA1c deciles.

Table 1—Relationship of severe hypoglycemia to mortality outcome in recent clinical trials assessing intensive glycemic control

| Clinical trial          | Incidence of severe hypoglycemia (%) | Mortality during study (% per year) | HR  
|------------------------|--------------------------------------|------------------------------------|-----
| ACCORD (10)            |                                      |                                    |     
| Standard glycemic control | 5.0                                 | 1.0                                |     
| No severe hypoglycemia |                                      |                                    |     
| Severe hypoglycemia (≥1 episode) | 4.9                                |                                    |     
| Intensive glycemic control | 15.9                                | 1.3                                |     
| No severe hypoglycemia |                                      |                                    |     
| Severe hypoglycemia (≥1 episode) | 2.8                                |                                    |     
| VADT (11,12)           |                                      |                                    |     
| Moderate glycemic control | 9.7                                 |                                    |     
| Intensive glycemic control | 21.1                                |                                    |     
| HR if severe hypoglycemia | 6.37                                |                                    |     
| All-cause mortality     |                                      |                                    |     
| Cardiovascular mortality | 3.73                                |                                    |     
| NICE-SUGAR study (14)  |                                      |                                    |     
| Intensive glycemic control | 6.8                                 |                                    |     
| Ordinary glycemic control | 0.5                                 |                                    |     
| HR for mortality in intensive control as compared with ordinary glycemic control | 1.14 |                                    |     

Weight gain

Weight gain accompanies insulin treatment. The magnitude of the weight gain is influenced by the level of the initial glycemic control, the treatment glycemic control achieved, the duration of insulin therapy, the insulin regimen used, and which combination of oral agents are concomitantly used (20–24). For example, in a study normalizing the HbA1c during 6 months of intensive multiple-dose insulin therapy, the mean weight gain was 8.7 kg (25). The 3-year data from the 4-T trial of insulin treatment regimens added to oral agents showed a 1.4% decrease in HbA1c and 6.4-kg weight gain in the patients assigned to prandial insulin treatment and a 1.3% decrease in HbA1c and 5.7-kg weight gain in the patients assigned to mixed insulin twice a day (11). In the ACCORD study, 28% of the intensively treated cohort and 14% of the ordinarily treated cohort
Starting insulin too early

gained >10 kg during a mean treatment period of ~3.5 years (26).

The mechanism responsible for the weight gain in insulin-treated patients is complex and can result in part from the decrease in glyclosuria; however, direct effects of insulin are clearly operative, since some other forms of treatment for hyperglycemia are either weight neutral (dipeptidyl peptidase-4 inhibitors) or actually cause weight loss (metformin, glucagon-like peptide 1 [GLP-1] receptor agonists).

The effect of the weight gain associated with insulin therapy on diabetes management and complications has not been determined. The increase in weight is associated with a striking increase in waist circumference that presumably is associated with an increase in visceral adiposity (11). In patients with type 1 diabetes, intensive insulin therapy is associated with a significant increase in body weight in many patients, and the consequences are the development of the metabolic syndrome in as many as 30–40% of the patients and a long-term increase in cardiovascular risk (27,28).

Risk of cancer

Recently, there has been a growing concern about the association of an increase in the incidence of specific cancers with the type of therapy of type 2 diabetes. It has been well established that pancreatic, hepatobiliary, colon, and breast cancer occur in a higher incidence in patients with type 2 diabetes than in control populations (29). The reasons for these associations may be multiple and include obesity, hyperglycemia, insulin resistance, and type of antihyperglycemic therapy. There are little data coming from prospective randomized controlled clinical trials. The vast bulk of available data come from retrospective analyses of various databases. The underlying pathophysiology of insulin resistance and the peripheral hyperinsulinemia accompanying exogenous insulin administration raise the specter that chronic intense insulin treatment might facilitate neoplastic growth.

A retrospective analysis comparing 465 patients with hepatocellular carcinoma to 618 patients with liver cirrhosis and 490 control subjects (30) found an odds ratio (OR) for hepatocellular carcinoma in patients treated with sulfonylureas or insulin to be 2.99 (95% CI 1.34–6.65, \( P = 0.007 \)), whereas that for patients treated with metformin was 0.33 (0.1–0.7, \( P = 0.006 \)). The prevalence of diabetes in the patients with hepatocellular carcinoma was 31.2%, and in the control subjects, the prevalence was 12.7%. Onset of diabetes preceded the diagnosis of hepatocellular carcinoma in 84.9% of the patients and by a mean of 141 months.

An analysis of antidiabetic therapy and the risk of pancreatic cancer in a retrospective case-controlled study (31) showed that after adjusting for age, sex, race, smoking, alcohol consumption, BMI, family history of cancer, duration of diabetes, and the use of insulin, the OR of developing pancreatic cancer was 4.99 (95% CI 2.59–9.61, \( P < 0.001 \)) in patients having had insulin therapy compared with patients who had never had insulin therapy. A similar result was noted in patients who had had diabetes for >2 years before their diagnosis of pancreatic carcinoma.

An analysis of a Saskatchewan Health database (32) of 10,309 new users of sulfonylurea or metformin with an average follow-up of 5.4 years found that sulfonylurea use was associated with an OR of cancer-related mortality (after adjusting for the chronic disease score) of 1.3 (95% CI 1.1–1.6) and insulin use of 1.9 (1.5–2.4). The recent nonrandomized prospective Zwolle Outpatient Diabetes Project Integrating Available Care (ZODIAC) study (33) adds to the observations that patients with diabetes have a higher standardized cancer mortality rate (1.47) and that metformin therapy decreases the HR to 0.43 (0.23–0.80). The Rosiglitazone Evaluated for Cardiovascular Outcomes in Oral Antidiabetic Therapy (RECORD) study (34) found that rosiglitazone decreased the development of pancreatic cancer over a 5.5-year period in patients with type 2 diabetes from 13 in the metformin/sulfonylurea-treated group to 2 (\( P = 0.0074 \)).

Insulin-sensitizing therapies and cardiovascular benefits in specific populations of type 2 diabetic patients

As noted in the introduction, there are relatively little data indicating that clinical outcomes are better with any one specific antihyperglycemic treatment compared with any other. Because of their effects in improving surrogate markers, it had been speculated that agents that reduce insulin resistance might have better outcomes than agents that provide insulin. Clinical trials such as Prospective Pioglitazone Clinical Trial in Macrovascular Events (PROActive) and RECORD failed to demonstrate such a benefit. Two studies (one a retrospective analysis of patients with type 2 diabetes after an acute myocardial infarction [36] and one a subanalysis of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOronary sYndrome [SYMPHONY] study [37]) suggested that survival and clinical outcomes after acute coronary artery disease is better after a treatment strategy emphasizing insulin-sensitizing therapies than insulin-providing therapies. As shown in Table 2, clinical outcomes in the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI-2D) trial were shown to be better in patients with type 2 diabetes and coronary heart disease undergoing coronary bypass surgery and treated with an insulin-sensitizing

| PCI stratum        | Revascularization | Medical therapy | \( P \) |
|--------------------|------------------|----------------|-------|
| Insulin sensitization | 21.1             | 20.4           | 0.36  |
| Insulin providing   | 24.9             | 21.7           | 0.28  |
| \( P \)             | 0.30             | 0.51           | 0.84  |

| CABG stratum       | Revascularization | Medical therapy | \( P \) |
|--------------------|------------------|----------------|-------|
| Insulin sensitization | 18.7             | 32.0           | 0.002 |
| Insulin providing   | 26.0             | 29.9           | 0.58  |
| \( P \)             | 0.066            | 0.51           | 0.07  |
strategy than in patients treated with an insulin-providing strategy (38). These data are somewhat tenuous but still suggest that insulin-providing strategies may not be as good in some patients with type 2 diabetes as insulin-sensitizing strategies.

**CONCLUSIONS**—Starting insulin therapy early in the course of chronic treatment of patients with type 2 diabetes would imply that there are unique benefits to insulin treatment. As addressed above, there is little evidence to support such a view. Insulin treatment is neither durable in maintaining glycemic control nor is unique in preserving β-cells. Better clinical outcomes than those that occur with other antihyperglycemic regimens have not been shown. The downside of insulin therapy is the need to increase the dose and the regimen complexity with time, the increase in severe hypoglycemia, and the potential increase in mortality as well as the potential increased risk for specific cancers.

What then should be the role for insulin therapy in patients with type 2 diabetes? Figure 4 presents two strategies that can take advantage of insulin therapies characteristics and minimize its downsides. There is a subset of patients whose initial presentation with type 2 diabetes is severe hyperglycemia with or without ketosis (39,40). In these individuals, the β-cell has become unresponsive to glucose, but can regain its sensitivity after several days to several weeks of euglycemia. Such individuals benefit from acute intensive insulin therapy applied for several weeks since it is quite effective in maintaining short-term euglycemia (40–42). About 30 to 40% of these patients will have a remission of their diabetes that may last for several years. The remainder can usually be switched to oral therapies quite effectively. For the vast majority of patients with type 2 diabetes, insulin therapy is best reserved until other therapies can no longer maintain the target glycemic goals. With the availability of GLP-1 receptor agonists that provide for glucose-regulated insulin secretion delivered through the portal vein and facilitate modest weight loss (43,44), it would seem appropriate to add insulin therapy in patients failing oral agents plus a GLP-1 receptor agonist. This therapy has shown promising results in several recent clinical studies (45), however, this combination is currently not approved for clinical use.

### Acknowledgments

H.E.L. is on the advisory boards for Amylin, Bioclin, and Merck; is a consultant for AstraZeneca and Intarcia; is a speaker for GlaxoSmithKline and sanofi-aventis; and is a shareholder of Merck and MetaCure. No other potential conflicts of interest relevant to this article were reported.

### References

1. Marchetti P, Dotta F, Lauro D, Purrello F. An overview of pancreatic beta-cell defects in human type 2 diabetes: implications for treatment. Regul Pept 2008;146:4–11
2. Ferrannini E, Cobelli C. The kinetics of insulin in man. II. Role of the liver. Diabetes Metab Rev 1987;3:365–397
3. Kido Y, Nakae J, Accili D. Clinical review 129: The insulin receptor and its cellular targets. J Clin Endocrinol Metab 2001;86:972–979
4. Savage DB, Petersen KF, Shulman GL. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol Rev 2007;87:507–520
5. Flier JS, Moller DE, Moses AC, et al. Insulin-mediated pseudoacromegaly: clinical and biochemical characterization of a syndrome of selective insulin resistance. J Clin Endocrinol Metab 1993;76:1533–1541
6. Kausch C, Bergemann C, Hamann A, Matthaei S. Insulin-mediated pseudoacromegaly in a patient with severe insulin resistance: association of defective insulin-stimulated glucose transport with impaired phosphatidylinositol 3-kinase activity in fibroblasts. Exp Clin Endocrinol Diabetes 1999;107:148–154
7. Yaqub A, Yaqub N. Insulin-mediated pseudoacromegaly: a case report and review of the literature. W V Med J 2008;104:12–15
8. Dib K, Whitehead JP, Humphreys PJ, et al. Impaired activation of phosphoinositide 3-kinase by insulin in fibroblasts from patients with severe insulin resistance and pseudoacromegaly: a disorder characterized by selective postreceptor insulin resistance. J Clin Invest 1998;101:1111–1120
9. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853
10. Turner RC, Cull CA, Frighi V, Holman RR. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005–2012
11. Holman RR, Farmer AJ, Davies MJ, et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736–1747
12. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with type 2 diabetes. JAMA 1999;361:1736–1747
Starting insulin too early

13. Knatterud GL, Klimt CR, Levin ME, Jacobson ME, Goldner MG, UGDP Group. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment. JAMA 1978;240:37–42

14. Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909

15. Skyler JS, Bergenstal R, Bonow RO, et al. Improved glycemic control with an insulin analog plus placebo compared with insulin plus metformin: a 24-week randomized study. JAMA 2005;293:2302–2312

16. Duckworth W, Abraira C, Moritz T, et al. Glucose control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009;32:187–192

17. Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716–1730

18. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009;360:1283–1297

19. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort. Lancet 2010;375:481–489

20. Yki-Jarvinen H, Kauppila M, Kujansuu E, Tulokas T, Vanamo R, Heikkila M. Combination therapies of insulin-sensitizing antihyperglycemic drugs and insulin with or without metformin associated with lower cancer risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 2010;59:1254–1260

21. Inzucchi SE, Masoudi FA, Wang Y, et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 2005;28:1680–1689

22. McGuire DK, Newby LK, Bhatkar MV, et al. Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 2004;147:246–252

23. Frye RL, August P, Brooks MM, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503–2515

24. Banerji MA, Chaiken RL, Lebovitz HE. Long-term normoglycemic remission in black newly diagnosed NIDDM subjects. Diabetes 1996;45:337–341

25. McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA. Near-normoglycemic remission in African-Americans with type 2 diabetes mellitus is associated with recovery of beta cell function. Diabet Med 2001;18:10–16

26. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on β-cell function and glycemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753–1760

27. Chen H-S, Wu T-E, Jap T-S, Hsiao L-C, Lee S-H, Lin H-D. Beneficial effects of insulin on glycemic control and β-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes 2008;57:1927–1932

28. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetesologia 2007;50:259–267

29. Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widell MH, Brodows RG; GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559–569

30. Yoon NM, Cavaghan MK, Brunelle RL, Roach P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clin Ther 2009;31:1511–1523